Key Takeaways:
• The FDA's February 2026 "Plausible Mechanism" framework is the most significant regulatory shift for individualized medicine, enabling faster approval of custom gene-editing therapies. Baby KJ’s story is an example of the impact of this change.
• The New York Times Op-Ed from April 2026 correctly identified that this change signals a new era where gene editing can now treat rare diseases systemically — but missed two critical barriers: the access gap (families don't know options exist) and the operations gap (coordinating 20+ vendors takes expertise and work hours not accounted for in the system).
• Baby KJ's base editing treatment for CPS1 deficiency was achieved in 6 months by an 80+ person team at CHOP/Penn, IGI, Danaher, and more — but that model doesn't scale. Properly trained Artificial Intelligence (LLMs) can reduce the number of people needed per project, as well as connect this service to every diagnosed patient. This is what’s needed to achieve the promise of the new genetic medicine era.
